ArticleCureus2026
Serpin B5 as a Potential Biomarker for the Diagnosis and Prognosis of Oral Squamous Cell Carcinoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Oral squamous cell carcinoma (OSCC) is a common malignancy of the head and neck region and remains to have relatively poor survival rates. Preliminary recognition of OSCC remains challenging as many patients remain asymptomatic until advanced stages, emphasizing the importance of earlier detection and accurate diagnosis. Existing diagnostic tools rely heavily on histological morphology, which has considerable variability among examiners. Serpin B5 is a serine protease inhibitor involved in vital cellular processes, including proliferation, invasion, and metastasis of malignant cells. We aimed to objectively document the expression trends in Serpin B5 in oral cancer as they relate to critical clinicopathological indicators. Study design Immunohistochemistry (IHC) was performed to detect Serpin B5 in the normal oral mucosa and in OSCC samples representing various clinical stages and histopathological grades. Computer-assisted analysis of IHC images was performed to consistently and objectively measure the relative abundance of Serpin B5. Results Serpin B5 expression analysis revealed a notable increase in OSCC tissues compared to normal oral mucosa. Furthermore, Serpin B5 expression showed significant correlations with the nodal status, clinical staging, and histopathological grading of OSCC. Conclusion This study documented the differential expression of Serpin B5 between normal oral mucosa and oral cancer specimens. Additionally, we found Serpin B5 expression to be significantly correlated with the histopathological grade, clinical stage, and nodal status of OSCC. The findings of this study underscore the potential application of Serpin B5 expression as a supplementary tool to aid in the diagnosis, prognosis, and monitoring of disease progression in oral cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.